Cargando…

Neoadjuvant therapy combined with surgery is superior to chemoradiotherapy in esophageal squamous cell cancer patients with resectable supraclavicular lymph node metastasis: a propensity score-matched analysis

BACKGROUND: Multiple clinical trials were conducted to evaluate the efficacy of neoadjuvant therapy in esophageal cancer but exhibited mixed results, indicating that the efficacy of neoadjuvant therapy remains controversial in the treatment of esophageal cancer. Our study was conducted to investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yongkui, Xu, Lei, Chen, Xiankai, Li, Haomiao, Liu, Qi, Zhang, Ruixiang, Xie, Hounai, Chen, Yongfeng, Yuan, Ling, Tan, Bo, Li, Yin, Xing, Wenqun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011204/
https://www.ncbi.nlm.nih.gov/pubmed/35434045
http://dx.doi.org/10.21037/atm-22-577
_version_ 1784687635349897216
author Yu, Yongkui
Xu, Lei
Chen, Xiankai
Li, Haomiao
Liu, Qi
Zhang, Ruixiang
Xie, Hounai
Chen, Yongfeng
Yuan, Ling
Tan, Bo
Li, Yin
Xing, Wenqun
author_facet Yu, Yongkui
Xu, Lei
Chen, Xiankai
Li, Haomiao
Liu, Qi
Zhang, Ruixiang
Xie, Hounai
Chen, Yongfeng
Yuan, Ling
Tan, Bo
Li, Yin
Xing, Wenqun
author_sort Yu, Yongkui
collection PubMed
description BACKGROUND: Multiple clinical trials were conducted to evaluate the efficacy of neoadjuvant therapy in esophageal cancer but exhibited mixed results, indicating that the efficacy of neoadjuvant therapy remains controversial in the treatment of esophageal cancer. Our study was conducted to investigate the value of neoadjuvant therapy in patients with esophageal cancer with supraclavicular lymph node metastases. METHODS: We retrospectively enrolled 231 patients who had resectable esophageal squamous cell carcinoma (ESCC) with supraclavicular lymph node metastases from June 2008 to November 2018. All patients were divided into three groups: the neoadjuvant therapy combined with surgery (Neo + S) group, the radical chemoradiotherapy (CRT) group, and the single radiotherapy (RT) group. Propensity score matching (PSM) was conducted to exclude the impact of potential interferences. Kaplan-Meier analysis, the log-rank test, and competitive risk model analysis were used to assess the efficacy of different therapeutic methods. RESULTS: Patients in the Neo + S group had a better 3-year survival rate (72.0% vs. 35.8%; P=0.005), progression-free survival (PFS) (24 vs. 14 months; P<0.0001), and lower 3-year tumor-specific mortality risk (25.1% vs. 53.7%; P=0.005) than those in the CRT group. Furthermore, patients in the CRT group had a better 3-year survival (30.1% vs. 18.6%; P=0.012) and lower 3-year tumor-specific mortality risk (57.9% vs. 76.8%; P=0.011) than those in the RT group. Additionally, the supraclavicular lymph node metastasis rate was higher than the mediastinal lymph node metastasis rate in patients with upper esophageal cancer compared to middle and lower esophageal cancer CONCLUSIONS: Neoadjuvant chemotherapy combined with surgery showed better efficacy than radical CRT in patients who had resectable ESCC with supraclavicular lymph nodes metastasis. Supraclavicular lymph nodes are more likely to be regional lymph nodes for upper and middle esophageal cancer.
format Online
Article
Text
id pubmed-9011204
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-90112042022-04-16 Neoadjuvant therapy combined with surgery is superior to chemoradiotherapy in esophageal squamous cell cancer patients with resectable supraclavicular lymph node metastasis: a propensity score-matched analysis Yu, Yongkui Xu, Lei Chen, Xiankai Li, Haomiao Liu, Qi Zhang, Ruixiang Xie, Hounai Chen, Yongfeng Yuan, Ling Tan, Bo Li, Yin Xing, Wenqun Ann Transl Med Original Article BACKGROUND: Multiple clinical trials were conducted to evaluate the efficacy of neoadjuvant therapy in esophageal cancer but exhibited mixed results, indicating that the efficacy of neoadjuvant therapy remains controversial in the treatment of esophageal cancer. Our study was conducted to investigate the value of neoadjuvant therapy in patients with esophageal cancer with supraclavicular lymph node metastases. METHODS: We retrospectively enrolled 231 patients who had resectable esophageal squamous cell carcinoma (ESCC) with supraclavicular lymph node metastases from June 2008 to November 2018. All patients were divided into three groups: the neoadjuvant therapy combined with surgery (Neo + S) group, the radical chemoradiotherapy (CRT) group, and the single radiotherapy (RT) group. Propensity score matching (PSM) was conducted to exclude the impact of potential interferences. Kaplan-Meier analysis, the log-rank test, and competitive risk model analysis were used to assess the efficacy of different therapeutic methods. RESULTS: Patients in the Neo + S group had a better 3-year survival rate (72.0% vs. 35.8%; P=0.005), progression-free survival (PFS) (24 vs. 14 months; P<0.0001), and lower 3-year tumor-specific mortality risk (25.1% vs. 53.7%; P=0.005) than those in the CRT group. Furthermore, patients in the CRT group had a better 3-year survival (30.1% vs. 18.6%; P=0.012) and lower 3-year tumor-specific mortality risk (57.9% vs. 76.8%; P=0.011) than those in the RT group. Additionally, the supraclavicular lymph node metastasis rate was higher than the mediastinal lymph node metastasis rate in patients with upper esophageal cancer compared to middle and lower esophageal cancer CONCLUSIONS: Neoadjuvant chemotherapy combined with surgery showed better efficacy than radical CRT in patients who had resectable ESCC with supraclavicular lymph nodes metastasis. Supraclavicular lymph nodes are more likely to be regional lymph nodes for upper and middle esophageal cancer. AME Publishing Company 2022-03 /pmc/articles/PMC9011204/ /pubmed/35434045 http://dx.doi.org/10.21037/atm-22-577 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Yu, Yongkui
Xu, Lei
Chen, Xiankai
Li, Haomiao
Liu, Qi
Zhang, Ruixiang
Xie, Hounai
Chen, Yongfeng
Yuan, Ling
Tan, Bo
Li, Yin
Xing, Wenqun
Neoadjuvant therapy combined with surgery is superior to chemoradiotherapy in esophageal squamous cell cancer patients with resectable supraclavicular lymph node metastasis: a propensity score-matched analysis
title Neoadjuvant therapy combined with surgery is superior to chemoradiotherapy in esophageal squamous cell cancer patients with resectable supraclavicular lymph node metastasis: a propensity score-matched analysis
title_full Neoadjuvant therapy combined with surgery is superior to chemoradiotherapy in esophageal squamous cell cancer patients with resectable supraclavicular lymph node metastasis: a propensity score-matched analysis
title_fullStr Neoadjuvant therapy combined with surgery is superior to chemoradiotherapy in esophageal squamous cell cancer patients with resectable supraclavicular lymph node metastasis: a propensity score-matched analysis
title_full_unstemmed Neoadjuvant therapy combined with surgery is superior to chemoradiotherapy in esophageal squamous cell cancer patients with resectable supraclavicular lymph node metastasis: a propensity score-matched analysis
title_short Neoadjuvant therapy combined with surgery is superior to chemoradiotherapy in esophageal squamous cell cancer patients with resectable supraclavicular lymph node metastasis: a propensity score-matched analysis
title_sort neoadjuvant therapy combined with surgery is superior to chemoradiotherapy in esophageal squamous cell cancer patients with resectable supraclavicular lymph node metastasis: a propensity score-matched analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011204/
https://www.ncbi.nlm.nih.gov/pubmed/35434045
http://dx.doi.org/10.21037/atm-22-577
work_keys_str_mv AT yuyongkui neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis
AT xulei neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis
AT chenxiankai neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis
AT lihaomiao neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis
AT liuqi neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis
AT zhangruixiang neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis
AT xiehounai neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis
AT chenyongfeng neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis
AT yuanling neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis
AT tanbo neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis
AT liyin neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis
AT xingwenqun neoadjuvanttherapycombinedwithsurgeryissuperiortochemoradiotherapyinesophagealsquamouscellcancerpatientswithresectablesupraclavicularlymphnodemetastasisapropensityscorematchedanalysis